#USA #San Diego #AlphaGen #Targeted Therapy #AACR 2026

AlphaGen Therapeutics to Present New Innovations at AACR 2026

AlphaGen Therapeutics, a pioneer in the biopharmaceutical field focusing on targeted alpha radiotherapies, has announced an exciting development in its research portfolio. The company will showcase preclinical studies of two novel alpha therapies at the 2026 Annual Meeting of the American Association for Cancer Research (AACR) in San Diego, California, from April 17 to 22. This event serves as an important platform for the latest advancements in cancer research and treatment, making it the ideal environment for AlphaGen to present its promising findings.

One of the leading candidates is [212Pb]Pb-AG1002, a next-generation, non-agonist radiopharmaceutical that targets the SSTR2 receptor. Early studies highlight its exceptional ability to bind to tumor cells, showing a significantly improved tumor-to-kidney (T/K) ratio compared to existing agonist radioligands. In multiple preclinical models, this therapy not only inhibited tumor growth effectively but also showcased a robust safety profile, which is paramount for any future clinical applications. The advantages of [212Pb]Pb-AG1002 suggest it could be a game changer for targeted therapies aimed at difficult-to-treat tumors.

The second groundbreaking program, [212Pb]Pb-AG1206, is a novel alpha radioligand therapy designed to target the fibroblast activation protein (FAP). This compound is built upon a macrocyclic peptide scaffold and features a remarkable binding affinity measured in picomolar concentrations. It exhibits rapid tumor accumulation and efficient renal clearance, which in turn contributes to a high T/K ratio, essential for therapeutic efficacy in oncology. Results from advanced preclinical studies indicate strong anti-tumor activity across various tumor models, reinforcing the potential of this therapy to deliver significant clinical benefits.

Dr. Mai-Jing Liao, CEO of AlphaGen Therapeutics, expressed enthusiasm about the forthcoming presentation, stating, _"We have developed a robust pipeline of novel and differentiated targeted alpha radiotherapies. We are pleased to showcase our exciting progress in two such programs at AACR Annual Meeting 2026._" The underlining message reflects AlphaGen's dedication to not only advancing its innovative treatments but also improving outcomes for patients facing challenging cancer diagnoses.

Upcoming Presentations at AACR 2026

Both therapies will be highlighted in detailed presentations:

• - [212Pb]Pb-AG1002 will be featured under the title Preclinical Evaluation of [212Pb]Pb-AG1002, a Next Generation SSTR2-Targeting, Non-Agonist Radiopharmaceutical during the session focused on Radiopharmaceutical Platforms for Theranostic Precision Oncology. This presentation is schedule for Tuesday, April 21, 2026, from 2 PM to 5 PM PDT. The relevant poster ID is 5811.

• - Similarly, [212Pb]Pb-AG1206 will also be presented similarly, under the title A Novel Fibroblast Activation Protein-Targeted Radioligand Therapy Demonstrated Excellent Efficacy and Safety Profile during the same session. Also scheduled for April 21, 2026, and coincidentally carrying the poster ID 5810.

As AlphaGen Therapeutics gears up for this invaluable opportunity to share its research, the medical community watches closely. Their advancements not only stand to impact how targeted therapies are viewed in modern oncology but could potentially transform treatment paradigms for patients with difficult-to-treat tumors.

In a world where cancer treatments are constantly evolving, AlphaGen's commitment to innovative research signifies a hope for breakthroughs that could redefine patient outcomes. As we approach the AACR 2026 meeting, the spotlight will undoubtedly shine on these promising developments.